Antihypertensives Market to 2016 - Generic Erosion Following Patent Expiry of Major ARBs to Impact the Market - GBI Research Reports

Antihypertensives Market to 2016 - Generic Erosion Following Patent Expiry of Major ARBs to Impact the Market

Antihypertensives Market to 2016 - Generic Erosion Following Patent Expiry of Major ARBs to Impact the Market - GBI Research Reports
Antihypertensives Market to 2016 - Generic Erosion Following Patent Expiry of Major ARBs to Impact the Market
Published Dec 31, 2010
103 pages — Published Dec 31, 2010
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, a leading business intelligence provider, has released its latest research, 'Antihypertensives Market to 2016 - Generic Erosion Following Patent Expiry of Major ARBs to Impact the Market'. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global antihypertensive market. The report analyzes the markets for antihypertensive disorders in the US, the top five markets in Europe (the UK, Germany, France, Italy and Spain), and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

Scope

The scope of this report includes:
- Annualized market data for the antihypertensive disorders market from 2002 to 2009, forecast forward to 2016.
- Analysis of the leading therapeutic segments, including hypertension and PAH.
- Analysis of the antihypertensive disorders market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the antihypertensive disorders market, including market size, annual cost of therapy and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development.
- Competitive benchmarking of leading companies. The key companies studied in this report are Novartis, Merck, AstraZeneca, United Therapeutics, Actelion and Pfizer.
- Key M&A activities, licensing agreements, that have taken place in 2009 in the global antihypertensive disorders market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

  
Source:
Document ID
GBIHC053MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Table of Contents36
1.1 List of Tables52
1.2 List of Figures72
2 Global Anti-Hypertensives Market: Introduction92
2.1 GBI Research Report Guidance101
3 Global Anti-Hypertensives Market: Market Overview1111
3.1 Introduction111
3.2 Revenue Forecasts for the Global Anti-Hypertensive Market121
Sales Value121
3.2.2 Annual Cost of Therapy131
3.2.3 Treatment Usage Patterns142
3.2.4 Treatment-Seeking Population161
3.2.5 Diagnosed Population171
3.2.6 Prescription Population181
3.3 Anti-Hypertension Disorders Market Drivers191
3.3.1 Steady Increase in the Hypertension and Pulmonary Arterial Hypertension Prevalence Population191
3.3.2 Uptake of Fixed Dose Combination Therapies due to Better Efficacy in Hypertension and PAH191
3.3.3 Patent Expiries of Branded Drugs and Entry of Generics will Reduce the Annual Cost of Therapy with Anti-Hypertensives 191
3.4 Anti-Hypertension Disorders Market Restraints201
3.4.1 Low Compliance in Hypertensive Patients201
3.4.2 Patent Expiries of Major Blockbusters Including Diovan, Avapro, Blopress/Atacand, Cozaar/Hyzaar and Tracleer, Pose a Threat to Market Revenues201
3.4.3 Low Treatment Seeking Behavior and Diagnosis in PAH 201
3.5 Generics Share in the Global Anti-Hypertension Market211
4 Global Anti-Hypertensives Market: Therapeutic Landscape2222
4.1 Hypertension221
4.1.1 Introduction221
4.1.2 Sales Value223
4.1.3 Annual Cost of Therapy251
4.1.4 Treatment Usage Patterns261
4.1.4.1 Treatment-Seeking Population271
4.1.4.2 Diagnosed Population281
4.1.4.3 Prescription Population291
4.1.5 Market Share by Geography303
4.2 Pulmonary Arterial Hypertension (PAH) Market331
4.2.1 Introduction332
4.2.2 Sales Value351
4.2.3 Annual Cost of Therapy361
4.2.4 Treatment Usage Patterns371
4.2.4.1 Treatment-Seeking Population381
4.2.4.2 Diagnosed Population391
4.2.4.3 Prescription Population 401
4.2.5 Market Share by Geography413
5 Global Anti-Hypertensives Market: Geographical Landscape4421
5.1 Geographical Break-up443
5.2 The US471
5.2.1 Sales Value471
5.2.2 Annual Cost of Therapy481
5.2.3 Treatment Usage Patterns491
5.2.4 Treatment-Seeking Population501
5.2.4.1 Diagnosed Population511
5.2.4.2 Prescription Population 521
5.3 Top Five Countries in Europe531
5.3.1 Sales Value531
5.3.2 Annual Cost of Therapy541
5.3.3 Treatment Usage Patterns551
5.3.3.1 Treatment-Seeking Population561
5.3.3.2 Diagnosed Population571
5.3.3.3 Prescription Population 581
5.4 Japan591
5.4.1 Sales Value591
5.4.2 Annual Cost of Therapy601
5.4.3 Treatment Usage Patterns611
5.4.3.1 Treatment-Seeking Population621
5.4.3.2 Diagnosed Population631
5.4.3.3 Prescription Population 641
6 Global Anti-Hypertensives Market: Pipeline Analysis6518
6.1 Introduction651
6.1.1 Research and Development Pipeline Hypertension666
6.1.2 Research and Development Pipeline Pulmonary Arterial Hypertension724
6.2 Profiles of Key Late-Stage Drugs in the Anti-Hypertension Market761
6.2.1 SPP635761
6.2.1.1 Introduction761
6.2.1.2 Efficacy761
6.2.1.3 Safety761
6.2.1.4 Clinical Study Details761
6.2.2 Pioglitazone771
6.2.2.1 Introduction771
6.2.2.2 Efficacy771
6.2.2.3 Safety771
6.2.2.4 Clinical Study Details771
6.2.3 LCZ696 781
6.2.3.1 Introduction781
6.2.3.2 Efficacy781
6.2.3.3 Safety Profile781
6.2.3.4 Clinical Study Details 781
6.2.4 QT1571 (imatinib)781
6.2.4.1 Introduction781
6.2.4.2 Efficacy781
6.2.4.3 Safety781
6.2.4.4 Clinical Study Details 791
6.2.5 Selexipag (NS-304, ACT-293987)791
6.2.5.1 Introduction791
6.2.5.2 Efficacy791
6.2.5.3 Safety791
6.2.5.4 Clinical Study Details 791
6.2.6 PS-433540 (DARA)801
6.2.6.1 Introduction801
6.2.6.2 Efficacy801
6.2.6.3 Safety801
6.2.6.4 Clinical Study Details801
6.2.7 Macitentan (ACT-064992, Actelion 1)801
6.2.7.1 Introduction801
6.2.7.2 Efficacy811
6.2.7.3 Safety811
6.2.7.4 Clinical Study Details811
6.2.8 Riociguat (BAY63-2521)811
6.2.8.1 6.2.8.1 Introduction811
6.2.8.2 Efficacy811
6.2.8.3 Safety811
6.2.8.4 Clinical Study Details812
7 Global Anti-Hypertensives Market: Competitive Landscape839
Market Share Analysis: Hypertension Disorders831
7.2 Competitive Profiling 841
7.2.1 Novartis841
7.2.1.1 Product Portfolio841
7.2.2 Merck851
7.2.2.1 Product Portfolio851
7.2.3 AstraZeneca861
7.2.3.1 Product Portfolio861
7.2.4 United Therapeutics871
7.2.4.1 Product Portfolio872
7.2.5 Actelion 891
7.2.5.1 Product Portfolio891
7.2.6 Pfizer 901
7.2.6.1 Product Portfolio902
8 Global Anti-Hypertensives Market: Strategic Consolidations927
8.1 Overview921
8.2 Deals by Type931
8.2.1 Eli Lilly Acquires ICOS in January 2007931
8.2.2 Abbott Laboratories Acquires Solvay Pharmaceuticals in February 2010931
8.2.3 Endo Pharmaceuticals to Acquire Qualitest Pharmaceuticals in 2010941
8.2.4 Jubilant Organosys Acquires Trinity Laboratories and Trigen Laboratories in March 2007941
R&D Licensing Agreements 941
8.3.1 Deals by Indication941
8.3.2 Deals by Phase951
8.3.3 Deals by Geography951
8.3.4 Phase II961
8.3.4.1 EG-PO42961
8.3.4.2 NS304961
8.3.4.3 Aviptadil961
8.3.5 Approved971
8.3.5.1 Diovan971
8.3.5.2 Olmotec971
8.3.5.3 Futuran971
8.3.5.4 Letairis971
8.3.5.5 Remodulin981
9 Global Anti-Hypertensives Market: Appendix995
9.1 Market Definitions991
9.2 Abbreviations992
9.3 Research Methodology1012
9.3.1 Coverage 1011
9.3.2 Secondary Research1011
9.3.3 Primary Research1011
9.3.4 Expert Panel Validation1021
9.4 Contact Us1021
9.5 Disclaimer1021
9.6 Sources1031

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Antihypertensives Market to 2016 - Generic Erosion Following Patent Expiry of Major ARBs to Impact the Market" Dec 31, 2010. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Antihypertensives-Market-to-2016-Generic-Erosion-Following-Patent-Expiry-of-Major-ARBs-to-Impact-the-Market-2115-136>
  
APA:
GBI Research Reports. (2010). Antihypertensives Market to 2016 - Generic Erosion Following Patent Expiry of Major ARBs to Impact the Market Dec 31, 2010. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Antihypertensives-Market-to-2016-Generic-Erosion-Following-Patent-Expiry-of-Major-ARBs-to-Impact-the-Market-2115-136>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.